Christina U. Lorentz

Director of Clinical Operations
Aronora, Inc

Presentation(s):

• LB 01.5 - Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis

  Sunday, July 10, 2022
  3:45 PM – 4:00 PM

• OC 28.5 - Coagulation FXI regulates endothelial cell barrier function by inducing VE-cadherin proteolysis in an ADAM10-dependent manner

  Sunday, July 10, 2022
  3:45 PM – 4:00 PM

• PB0553 - The antithrombotic protein C activator thrombin mutant W215A/E217A (AB002, E-WE) is slowly inhibited by the endogenous thrombin inhibitors antithrombin, protein C inhibitor, and heparin cofactor II

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 65.3 - A Phase 2 Trial Evaluating the Safety and Antithrombotic Efficacy of AB002, a First-in-class Protein C Activator in End-stage Renal Disease Patients on Heparin-free Hemodialysis

  Tuesday, July 12, 2022
  3:15 PM – 3:30 PM